clinical trial · NCT07044271
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
Eli Lilly and Company·phase1·completed·n = 120
HealthyOlomorasib
brief summary
The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.
started
Jul 11, 2025
primary completion
Nov 8, 2025
completion
Nov 8, 2025
last updated
May 29, 2026
official title
An Open-Label, Randomized, 3-Way Crossover Study Comparing the Pharmacokinetics of Multiple Olomorasib (LY3537982) Capsules
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol